Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16


An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors.

Indarte M, Puentes R, Maruggi M, Ihle NT, Grandjean G, Scott M, Ahmed Z, Meuillet EJ, Zang S, Lemos R Jr, Du-Cuny L, Layng FIAL, Correa RG, Bankston LA, Liddington RC, Kirkpatrick L, Powis G.

Cancer Res. 2019 Jun 15;79(12):3100-3111. doi: 10.1158/0008-5472.CAN-18-2372. Epub 2019 Apr 30.


Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer.

Bar-Peled L, Kemper EK, Suciu RM, Vinogradova EV, Backus KM, Horning BD, Paul TA, Ichu TA, Svensson RU, Olucha J, Chang MW, Kok BP, Zhu Z, Ihle NT, Dix MM, Jiang P, Hayward MM, Saez E, Shaw RJ, Cravatt BF.

Cell. 2017 Oct 19;171(3):696-709.e23. doi: 10.1016/j.cell.2017.08.051. Epub 2017 Sep 28.


The Pten-Parkin Axis: At the Nexus of Cancer and Neurodegeneration.

Ihle NT, Abraham RT.

Mol Cell. 2017 Mar 16;65(6):959-960. doi: 10.1016/j.molcel.2017.02.030.


Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine.

Zhu Z, Ihle NT, Rejto PA, Zarrinkar PP.

BMC Genomics. 2016 Jun 13;17:455. doi: 10.1186/s12864-016-2807-y.


Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.

Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G.

J Natl Cancer Inst. 2012 Feb 8;104(3):228-39. doi: 10.1093/jnci/djr523. Epub 2012 Jan 13.


PI-3-Kinase inhibitors in colorectal cancer.

Ihle NT, Powis G, Kopetz S.

Curr Cancer Drug Targets. 2011 Feb;11(2):190-8. Review.


Inhibitors of phosphatidylinositol-3-kinase in cancer therapy.

Ihle NT, Powis G.

Mol Aspects Med. 2010 Apr;31(2):135-44. doi: 10.1016/j.mam.2010.02.003. Epub 2010 Feb 20. Review.


The biological effects of isoform-specific PI3-kinase inhibition.

Ihle NT, Powis G.

Curr Opin Drug Discov Devel. 2010 Jan;13(1):41-9. Review.


Inhibiting PI-3-K for glioma therapy.

Powis G, Ihle NT, Yung WK.

Cell Cycle. 2009 Feb 1;8(3):335. Epub 2009 Feb 1. No abstract available.


Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity.

Ihle NT, Lemos R, Schwartz D, Oh J, Halter RJ, Wipf P, Kirkpatrick L, Powis G.

Mol Cancer Ther. 2009 Jan;8(1):94-100. doi: 10.1158/1535-7163.MCT-08-0714.


Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy.

Ihle NT, Powis G.

Mol Cancer Ther. 2009 Jan;8(1):1-9. doi: 10.1158/1535-7163.MCT-08-0801. Review.


Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.

Ihle NT, Lemos R Jr, Wipf P, Yacoub A, Mitchell C, Siwak D, Mills GB, Dent P, Kirkpatrick DL, Powis G.

Cancer Res. 2009 Jan 1;69(1):143-50. doi: 10.1158/0008-5472.CAN-07-6656.


The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling.

Williams R, Baker AF, Ihle NT, Winkler AR, Kirkpatrick L, Powis G.

Cancer Chemother Pharmacol. 2006 Oct;58(4):444-50. Epub 2006 Feb 17.


The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.

Ihle NT, Paine-Murrieta G, Berggren MI, Baker A, Tate WR, Wipf P, Abraham RT, Kirkpatrick DL, Powis G.

Mol Cancer Ther. 2005 Sep;4(9):1349-57.


Stability of phosphoprotein as a biological marker of tumor signaling.

Baker AF, Dragovich T, Ihle NT, Williams R, Fenoglio-Preiser C, Powis G.

Clin Cancer Res. 2005 Jun 15;11(12):4338-40.


Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling.

Ihle NT, Williams R, Chow S, Chew W, Berggren MI, Paine-Murrieta G, Minion DJ, Halter RJ, Wipf P, Abraham R, Kirkpatrick L, Powis G.

Mol Cancer Ther. 2004 Jul;3(7):763-72.

Supplemental Content

Support Center